Why Tirzepatide Works Well

The SURMOUNT-4 phase 3 clinical trial, led by researchers at Weill Cornell Medicine and NewYork-Presbyterian, investigated the effectiveness of anti-obesity drugs, particularly tirzepatide, in maintaining weight loss over the long term. This trial revealed that individuals who stopped taking the medication experienced significant weight regain within a year, while those who continued using it not only sustained their weight loss but also saw improvements in metabolic and cardiovascular health.

Tirzepatide, a GLP-1 receptor agonist initially developed to treat type 2 diabetes, has shown promising results in promoting weight loss. In a previous study, participants experienced a 20% reduction in body weight over 72 weeks, leading to FDA approval for weight loss treatment in individuals with a BMI of 30 or higher. However, researchers were unsure if the weight loss would persist without active treatment, prompting the SURMOUNT-4 trial.

During the trial, participants who continued taking tirzepatide maintained their weight loss and experienced additional improvements in various health indicators compared to those who switched to a placebo. However, individuals in the placebo group regained a significant portion of their lost weight, highlighting the need for long-term medication to sustain weight loss.

Tirzepatide works by mimicking natural hormones in the body that regulate appetite and promote feelings of fullness. While side effects such as nausea and diarrhea were observed, they typically resolved over time, and few participants discontinued treatment due to adverse effects.

Overall, the findings suggest that anti-obesity drugs like tirzepatide may be effective tools for managing weight loss but may require ongoing use to maintain results. Obesity is considered a chronic condition similar to diabetes or high blood pressure, emphasizing the need for chronic treatment approaches.

You can read more about it here